Thai PBS Thai PBS
COVID still a killer for 500,000 vulnerable people – but Thailand has new defense

COVID still a killer for 500,000 vulnerable people – but Thailand has new defense

13 Sept 13:33 Key points summarised by AI
  • Thailand is deploying AstraZeneca's long-acting antibody (LAAB) combination, Evusheld, to shield 500,000 immunocompromised citizens highly vulnerable to severe COVID-19.
  • Evusheld, approved for emergency use in Thailand, provides crucial pre-exposure protection against symptomatic COVID-19, including dominant Omicron subvariants, for those with weak immune systems.
  • The initial 250,000 doses prioritize patients with end-stage kidney disease, organ transplants, and cancer, with the government planning to extend LAAB treatment to all eligible immunocompromised individuals.
Read full article
News 1/1
Skip > Skip >